Skip to main content
Back
Watch Compare

Dermata Therapeutics, Inc.

Data quality: 83%
Also listed as DRMAW Nasdaq
DRMA
Nasdaq Manufacturing Chemicals
$1.21
▼ $0.07 (-5.47%)
Mkt Cap: 4.87 M
Price
$1.21
Mkt Cap
4.87 M
Day Range
$1.20 — $1.29
52-Week Range
$1.10 — $9.90
Volume
52,255
Open $1.27
50D / 200D Avg
$1.52
20.47% below
50D / 200D Avg
$3.77
67.94% below

Quick Summary

Key Takeaways

Negative free cash flow of -7.76 M

Growth

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-157.89%
Below sector avg (-53.41%)
ROIC-104.87%
Net MarginN/A
Op. MarginN/A

Safety

Debt / Equity
N/A
Current RatioN/A
Interest CoverageN/A

Valuation

PE (TTM)
-0.64
Above sector avg (-1.48)
P/B Ratio1.23
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1364 peers)
Metric Stock Sector Median
P/E -0.6 -1.5
P/B 1.2 1.6
ROE % -157.9 -53.4
Net Margin % — -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3

ETFs Holding This Stock

AVSE logo AVSE Avantis Responsible Emerging Markets Equity ETF
0.01% weight
AVES logo AVES Avantis Emerging Markets Value ETF
0.00% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -7.56 M
ROE -157.89% ROA -129.07%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -7.76 M
ROIC -104.87% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio N/A
Interest Coverage N/A Asset Turnover N/A
Working Capital N/A Tangible Book Value 3.96 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0.64 Forward P/E N/A
P/B Ratio 1.23 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -159.40%
Market Cap 4.87 M Enterprise Value 202,666.0
Per Share
EPS (Diluted TTM) -8.16 Revenue / Share N/A
FCF / Share -1.93 OCF / Share -1.93
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 102.63%
SBC-Adj. FCF -7.89 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -7.56 M -12.29 M -7.79 M -9.61 M -7.90 M
EPS (Diluted) -8.16 -8.03 — — —
Gross Profit — — — — —
Operating Income -7.77 M -12.51 M -8.04 M -9.67 M -7.86 M
EBITDA — — — — —
R&D Expenses 2.93 M 8.20 M 4.07 M 5.65 M 3.46 M
SG&A Expenses 4.84 M — — — —
D&A — — — — 0.0
Interest Expense — — — 63,573.0 45,613.0
Income Tax — 0.0 0.0 0.0 0.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 7.86 M 3.53 M 7.98 M 6.94 M 11.62 M
Total Liabilities 1.64 M 1.97 M 1.62 M 922,634.0 1.52 M
Shareholders' Equity 6.22 M 1.56 M 6.36 M 6.02 M 10.11 M
Total Debt — — — — —
Cash & Equivalents 7.52 M — — 6.24 M 10.80 M
Current Assets — — — — 11.62 M
Current Liabilities — — — — 1.52 M